Polypharmacy and bone fracture risk in patients with type 2 diabetes: The Fukuoka Diabetes Registry

Yuji Komorita, Toshiaki Ohkuma, Masanori Iwase, Hiroki Fujii, Yutaro Oku, Taiki Higashi, Ayaka Oshiro, Wakako Sakamoto, Masahito Yoshinari, Udai Nakamura, Takanari Kitazono

研究成果: Contribution to journalArticle査読

抄録

Aims: To prospectively investigate the association between the number of prescribed drugs and the fracture risk in patients with type 2 diabetes. Methods: Japanese participants with type 2 diabetes (n = 4,706; 2,755 men, 1,951 postmenopausal women; mean age, 66 years) were followed for a median of 5.3 years and grouped on the basis of the number of prescribed drugs at baseline. The main outcomes were fractures at any anatomic site and fragility fractures (fractures at hip and spine sites). Results: During follow-up, any fracture occurred in 662 participants. The overall age- and sex-adjusted fracture incidence rates per 1,000 person-years were 21.2 (0–2 drugs), 28.1 (3–5 drugs), 37.7 (6–8 drugs), and 44.0 (≥9 drugs) (p for trend < 0.001). Compared with 0–2 drugs, the multivariate-adjusted hazard ratios (HRs) (95% confidence intervals [CIs]) for fractures were 1.34 (1.07–1.68) for 3–5 drugs, 1.76 (1.37–2.26) for 6–8 drugs, and 1.71 (1.27–2.31) in ≥ 9 drugs. The multivariate-adjusted HR (95% CI) per increment in drugs was 1.05 (1.02–1.08) (p < 0.001). Similar tendencies were observed for fragility fractures. Conclusions: A greater number of prescribed drugs is associated with an increased bone fracture risk in patients with type 2 diabetes.

本文言語英語
論文番号109097
ジャーナルDiabetes Research and Clinical Practice
181
DOI
出版ステータス出版済み - 11 2021

All Science Journal Classification (ASJC) codes

  • 内科学
  • 内分泌学、糖尿病および代謝内科学
  • 内分泌学

フィンガープリント

「Polypharmacy and bone fracture risk in patients with type 2 diabetes: The Fukuoka Diabetes Registry」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル